Chemodex

Minocycline hydrochloride

As low as CHF 71.00
In stock
Only %1 left
CDX-M0620-M250250 mgCHF 71.00
CDX-M0620-G0011 gCHF 155.00
NEW
 
More Information
Product Details
Synonyms MinCyc; Minomycin; Klinomycin; Minocin; NSC141993
Product Type Chemical
Properties
Formula C23H27N3O7 . HCl
MW 493.94
CAS 13614-98-7
RTECS QI7630500
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance Yellow powder.
Solubility Soluble in DMSO (30mg/ml), DMF, methanol or water (5mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key GLMUAFMGXXHGLU-VQAITOIOSA-N
Smiles CN(C)[C@H](C(O)=C1C(N)=O)[C@@]2([H])[C@@](C(O)=C(C(C3=C(O)C=CC(N(C)C)=C3C4)=O)[C@]4([H])C2)(O)C1=O.Cl
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description
Minocycline, a semi-synthetic second-generation tetracycline, is a broad spectrum antibiotic with bacteriostatic function. Tetracyclines, including minocycline, function by binding to the 30S ribosomal subunit, thereby preventing charged tRNA from delivering amino acids to elongate the protein chain and form cellular protein. This disruption results in a bacteriostatic effect on the prokaryotic cell, leading to the loss of its ability to grow or replicate. Being lipid-soluble compounds, tetracyclines can traverse hydrophobic barriers such as biological membranes. It is orally active and brain penetrant. Apart from its efficacy against gram-positive and gram-negative bacteria, minocycline also exhibits antioxidant, anti-apoptotic, anti-tumor, anti-inflammatory, immunomodulatory, and neuroprotective properties. Minocycline has anti-inflammatory properties and inhibits neuroinflammation in pre-plaque of Alzheimer's disease-like amyloid pathology through inhibition of key inflammatory enzymes like inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP-9) and 5-lipoxygenase. Minocycline inhibits endothelial cell proliferation and angiogenesis, and inhibit the enzymatic activity of poly(ADP-ribose) polymerase-1 (PARP-1). Minocycline exhibits anti-tumor activity in glioma by inhibiting membrane type 1 matrix metalloproteinase (MT1-MMP). Minocycline increases cognition and neuronal differentiation.
Product References
(1) R.J. Tamargo, et al.; Cancer Res. 51, 672 (1991) | (2) S. Gilbertson-Beadling, et al.; Cancer Chemother. Pharmacol. 36, 418 (1995) | (3) M. Kloppenburg, et al.; Clin. Exp. Immunol. 102, 635 (1995) | (4) S. Parangi, et al.; PNAS 93, 2002 (1996) | (5) T. Tikka, et al.; J. Neurosci. 21, 2580 (2001) | (6) V. Brundula, et al.; Brain 125, 1297 (2002) | (7) F. Giuliani, et al.; J. Leukoc. Biol. 78, 135 (2005) | (8) M.C. Zink, et al.; JAMA 293, 2003 (2005) | (9) S.S.V. Padi & S.K. Kulkarni; Eur. J. Pharmacol. 601, 79 (2008) | (10) R. Tao, et al.; J. Cardiovasc. Pharmacol. 56, 659 (2010) | (11) N. Garrido-Mesa, et al.; Pharmacol. Res. 67, 18 (2013) | (12) N. Garrido-Mesa, et al.; Br. J. Pharmacol. 169, 337 (2013) | (13) D.J. Ritchie & A. Garavaglia-Wilson; Clin. Infect. Dis. 59, S374 (2014) | (14) O.M. Dean, et al.; Clin. Psychopharmacol. Neurosci. 12, 180 (2014) | (15) J.A. Brenes-Salazar; Can. J. Physiol. Pharmacol. 93, 863 (2015) | (16) J. Budni, et al.; Curr. Alzheimer Res. 13, 1319 (2016) | (17) A.R. Afshari, et al.; J. Oncol. 2020, 8659802 (2020) | (18) D.A. Shin, et al.; J. Pain Res. 14, 139 (2021) | (19) S. Singh, et al.; Curr. Mol. Pharmacol. 14, 1046 (2021) | (20) A. Rezaei, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 397, 2835 (2024)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.